Anshan Hifichem Co (300758) Fair Value & Analysis
Basic Materials · CN · Market cap 5.0B CNY
Fair value as of: Jul 9, 2026
From 15 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥3.16 to ¥3.36 (+6.4%) since Jun 24, 2026. Share price −1.6% over the past month.
Below-average quality, and screening another 70% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.94). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥5.62 – ¥20.13 · fair‑value band ¥2.36 – ¥3.94 · the ¥11.39 price screens above the ¥3.36 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Anshan Hifichem Co (300758) currently trades at ¥11.39, while our model-based Fair Value estimate is ¥3.36, implying the stock looks roughly 70.5% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Anshan Hifichem Co generated revenue of 1.5B CNY at a net margin of 3.0%. Revenue grew 9.8% year over year. It earns a return on equity of 2.5%. Net debt stands at 490M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥2.36 (bear case) to ¥3.94 (bull case); at ¥11.39, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -58% fair-value upside, at -70%, 300758 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Asset-Based (¥2.97) versus Earnings-Based (¥2.03). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Anshan Hifichem Co., Ltd. engages in the research, development, manufacture, and sale of high-performance organic pigments, dyestuff, and intermediates in China.
Full company description
Anshan Hifichem Co., Ltd. engages in the research, development, manufacture, and sale of high-performance organic pigments, dyestuff, and intermediates in China. It offers lead chrome yellow and molybate orange pigments, solvent dyestuff, and inks for use in various industries, such as Vehicle paint and refinish paint, industrial coating, powder coating, 3c coatings, construction, architecture paint, container and marine coating, food packaging, toys application, lamination ink, Inkjet printing, and packaging ink. Anshan Hifichem Co., Ltd. was founded in 2006 and is headquartered in Anshan, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Anshan Hifichem Co reported revenue of ¥1.5B in FY2025 versus ¥1.3B in FY2021, a compound +2.6%/yr. Reported net income was ¥61.2M in FY2025, compounding −23.7%/yr from FY2021.
300758 screens 70% overvalued. Compare with Linde plc →
Peer Group
Specialty Chemicals · 676 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $489.98 | $222.03 | -55% |
| Nan Ya Plastics Corporation 1303 | 181.50 TWD | 255.83 TWD | +41% |
| Wanhua Chemical Group 600309 | ¥70.04 | ¥68.03 | -3% |
| Novozymes A/S NSISB | kr 428.20 | kr 179.66 | -58% |
| Asian Paints Limited ASIANPAINT | ₹2,689 | ₹668.81 | -75% |
| Solar Industries India Limited SOLARINDS | ₹18,236 | ₹2,793 | -85% |
| Pidilite Industries Limited PIDILITIND | ₹1,560 | ₹351.84 | -77% |
| PT Chandra Asri Pacific Tbk TPIA | 1,805 IDR | 2,888 IDR | +60% |
| Linde India Limited LINDEINDIA | ₹7,115 | ₹757.93 | -89% |
| Berger Paints India Limited BERGEPAINT | ₹493.70 | ₹164.29 | -67% |
Compare Anshan Hifichem Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Anshan Hifichem Co (300758) overvalued or undervalued?
What is the fair value of 300758?
What is the quality score of 300758?
What is the revenue of Anshan Hifichem Co (300758)?
What is the net profit margin of 300758?
Does Anshan Hifichem Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Anshan Hifichem Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.